Development and validation of a cost-utility model for Type1 diabetes mellitus

被引:8
|
作者
Wolowacz, S. [1 ]
Pearson, I. [1 ]
Shannon, P. [2 ]
Chubb, B. [3 ]
Gundgaard, J. [4 ]
Davies, M. [5 ]
Briggs, A. [6 ]
机构
[1] RTI Hlth Solut, Hlth Econ, Manchester, Lancs, England
[2] RTI Hlth Solut, Patient Reported Outcomes, Manchester, Lancs, England
[3] Novo Nordisk Ltd, European Hlth Econ & Outcomes Res, Gatwick, W Sussex, England
[4] Novo Nordisk AS, Hlth Econ & HTA, Bagsvaerd, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
关键词
RISK-FACTORS; COMPLICATIONS; DISEASE; NEUROPATHY; EURODIAB; COHORT; ONSET;
D O I
10.1111/dme.12663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.
引用
收藏
页码:1023 / 1035
页数:13
相关论文
共 50 条
  • [1] Basal Insulin Regimens for Adults with Type 1 Diabetes Mellitus: A Cost-Utility Analysis
    Dawoud, Dalia
    Fenu, Elisabetta
    Higgins, Bernard
    Wonderling, David
    Amiel, Stephanie A.
    VALUE IN HEALTH, 2017, 20 (10) : 1279 - 1287
  • [2] Assessing the cost-effectiveness of Type1 diabetes interventions: the Sheffield Type1 Diabetes Policy Model
    Thokala, P.
    Kruger, J.
    Brennan, A.
    Basarir, H.
    Duenas, A.
    Pandor, A.
    Gillett, M.
    Elliott, J.
    Heller, S.
    DIABETIC MEDICINE, 2014, 31 (04) : 477 - 486
  • [3] Cost-utility of empagliflozin in patients with type 2 diabetes mellitus at high cardiovascular risk
    Weeda, Erin
    Nguyen, Elaine
    Coleman, Craig
    Nair, Suresh
    PHARMACOTHERAPY, 2017, 37 (12): : E168 - E168
  • [4] Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus
    Vijan, S
    Hofer, TP
    Hayward, RA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (07): : 889 - 896
  • [5] COST-UTILITY OF EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN COLOMBIA
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A172 - A172
  • [6] Presentation of Newly Diagnosed Type1 Diabetes Mellitus
    Khan, Khalid
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 2): : 480 - 480
  • [8] Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
    Men, Peng
    Liu, Tianbi
    Zhai, Suodi
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 2823 - 2831
  • [9] Prevention of type 2 diabetes mellitus. Cost-utility of lifestyle modification compared to metformin treatment
    Hoffmann, B
    Gericke, CA
    MEDIZINISCHE KLINIK, 2005, 100 (10) : 686 - 688
  • [10] COST-UTILITY EVALUATION OF CONTINUING EDUCATION FOR THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS USERS IN PERNAMBUCO - BRAZIL
    Aquino, C. M.
    Lima, R. C.
    Bezerra, A. F.
    Sousa, I. M.
    Cesse, E. A.
    Carvalho, E. M.
    Fontbonne, A.
    VALUE IN HEALTH, 2015, 18 (03) : A14 - A14